contact us  versant ventures search for versant ventures on linkedin share lp access contact us careers contact us at one of our five offices san francisco one sansome suite  san francisco ca  phone   fax   new york  west st street suite  new york ny  phone   minneapolis  equitable drive suite  eden prairie mn  phone   basel switzerland versant ventures switzerland gmbh aeschenvorstadt  ch basel switzerland phone      canada versant ventures canada limited  great northern way suite  vancouver bc vt t phone   home  versant ventures search for versant ventures on linkedin share lp access contact us careers ive built two companies with versant ventures and value their distinctive investment approach they have a clear understanding of the recipe for startup company success and represent a premium brand in healthcare venture capital today david clapper  minerva surgical versant invested in life the people at versant understand the entrepreneurial process they take a longterm view of the portfolio company and help provide perspective and support in times thick and thin amar sawhney  ocular therapeutix versant invested in life versant has been and continues to be a superb investor they provide insight and counsel to our efforts and their willingness to roll up their sleeves to problem solve with us has been invaluable michael d clayman md  flexion therapeutics versant invested in life featured case study biotechnology quanticel pharmaceuticals quanticel technology is based on the work of stanford researchers and company founders stephen quake and michael clarke versant had backed other genomic technologies invented by quake and moved quickly to incubate quanticel in  shortly after the company was founded the idea behind quanticel’s singlecell genomic analysis technology is to unlock the mystery of cancer drug resistance through the analysis of tumor cell heterogeneity as a tumor grows and cancer cells rapidly replicate the genetic diversity of these cells increases full quanticel pharmaceuticals case study news highlights venatorx pharmaceuticals raises  million series b venatorxfinal repare therapeutics raises us million series a repare therapeutics raises us million series a crispr therapeutics announces the appointment of jon terrett phd to head of immunooncology research and translation crispr appoints jon terrett versant ventures launches jecure therapeutics jecureseriesa portfolio overview  versant ventures search for versant ventures on linkedin share lp access contact us careers partnering to improve healthcare we are proud of our track record of working with extraordinary scientists entrepreneurs and business leaders to build transformational companies that impact and improve healthcare we invest our time talent leadership and expertise in all our portfolio partnerships we pursue opportunities where we can add value through our handson collaborative approach and devote the appropriate mix of strategic advice domain expertise and capital to help accelerate their growth we invest in life and in success since our inception in  we have invested in over  seed early and growth stage companies – of which  have gone public or been acquired to date contact us  versant ventures search for versant ventures on linkedin share lp access contact us careers contact us at one of our five offices san francisco one sansome suite  san francisco ca  phone   fax   new york  west st street suite  new york ny  phone   minneapolis  equitable drive suite  eden prairie mn  phone   basel switzerland versant ventures switzerland gmbh aeschenvorstadt  ch basel switzerland phone      canada versant ventures canada limited  great northern way suite  vancouver bc vt t phone   versant overview  versant ventures search for versant ventures on linkedin share lp access contact us careers propelling life sciences companies versant ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies the firm invests across the healthcare sector and at all stages of company development with an emphasis on the discovery and development of novel therapeutics with  billion under management and offices in north america and europe versant has built a team with deep investment operating and scientific expertise that enables a handson approach to company building since the firm’s founding in  nearly  versant companies have achieved successful acquisitions or ipos versant in europe versant ventures has a team in basel switzerland dedicated to working with entrepreneurs industry and leading academics across europe the team has decades of experience in the pharmaceutical and biotechnology industries including global roles in drug discovery research and product development for companies such as roche novartis and lilly versant’s basel office is led by tom woiwode guido magni and gianni gromo   medical devices archives  versant ventures search for versant ventures on linkedin share lp access contact us careers medical devices ebb therapeutics oakmont pa ebb is developing a therapeutic device for insomnia inari medical irvine ca inari medical is a medical device company pioneering innovative devices for the interventional treatment of vascular thrombi and emboli metavention minneapolis mn metavention is developing novel interventional therapies for type  diabetes sebacia duluth ga sebacia is developing a medical device to cure acne zyga technology minneapolis mn zyga is developing and marketing innovative minimally invasive surgical solutions to treat conditions of the spine rox medical san clemente ca rox is developing devices for treatment of diseases of the respiratory system respicardia minnetonka mn respicardia is developing an implantable system to treat central sleep apnea in patients with heart failure orametrix richardson tx orametrix is a leading industry provider of innovative d technology solutions facilitating and improving the quality of orthodontic care neurotech pharmaceuticals lincoln ri neurotech pharmaceuticals is pioneering encapsulated cell technology as a drug delivery platform for retinal degenerative diseases minerva surgical cupertino ca minerva is developing next–generation technology for treating excessive menstrual bleeding microfabrica van nuys ca microfabrica has developed a broad microscale platform for minimally invasive procedures and for complex dynamic implants intuity medical sunnyvale ca intuity medical formerly rosedale is developing a handheld all inone discrete bloodbased diagnostic platform that will enhance glucose monitoring for diabetic patients holaira plymouth mn novel devices to treat obstructive lung disease  previously innovative pulmonary solutions halscion suwanee ga halscion is advancing a solution for reduction of surgically induced scarring forsight vision  menlo park ca forsight vision is evaluating a variety of technologies to address important unmet patient needs in key ophthalmic markets forsight vision  menlo park ca forsight vision  inc is developing novel ocular drug delivery technologies ceterix orthopedics fka suturepro technologies inc menlo park ca ceterix is developing a new orthopedic suturing technology that is focused on improving easeofuse and operative speed celula san diego ca celula is developing rare cell isolation technology for diagnostic and therapeutic purposes benvenue medical santa clara ca benvenue medical is developing and marketing innovative spine repair technology alterg fremont ca alterg is marketing its “gtrainer” technology a treadmill system that reduces the users’ body weightimpact of running and thereby enhances physical rehabilitation from orthopedic or neurological injury acufocus irvine ca acufocus is developing a corneal implant to treat presbyopia the need for reading glasses portfolio companiesbiotechnology biotechnology exits  ipos medical devices medical device exits  ipos additional investments additional investment exits discovery engines case studies amira pharmaceuticals inception  inc quanticel pharmaceuticals biotechnology archives  versant ventures search for versant ventures on linkedin share lp access contact us careers biotechnology venatorx pharmaceuticals malvern pa venatorx is a developing nextgeneration antibiotics to treat multidrug resistant mdr infections vividion therapeutics san diego ca vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteomewide drug and target discovery repare therapeutics montreal canada repare is developing new precision oncology drugs for patients that target specific vulnerabilities of tumor cells northern biologics toronto canada northern biologics is developing novel therapeutic antibodies for the treatment of human diseases in oncology fibrosis and other diseases piqur therapeutics basel switzerland piqur is a swiss pharmaceutical company focusing on the discovery and development of innovative small molecule therapeutics based on lipid kinase pik and mtor inhibition for the treatment of cancer as well as other indications anokion ecublens switzerland anokion is focused on leveraging its proprietary immune tolerance technology to develop novel protein therapeutics and treatments for autoimmune diseases mosaic biomedicals barcelona spain mosaic biomedicals is a barcelonabased company that develops personalized cancer treatments with a dual mechanism of action to eliminate cancer stem cells and reactivate the tumor’s immune system mosaic’s innovative treatments are derived from a deep understanding of the tumor biology and aim to offer safer and more effective options to cancer patients aavlife paris france aavlife is a gene therapy company focused on developing treatments for rare diseases with great unmet medical need inception ibd san diego ca inception ibd is focused on translating academic discoveries in the field of ibd into firstinclass small molecule drugs crispr therapeutics basel switzerland crispr therapeutics is making use of significant advances in the field of gene editing and focused on translating the crisprcas technology in truly transformational therapeutics for common and rare genetic diseases audentes therapeutics san francisco ca audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious rare diseases through the application of gene therapy technology gensight biologics tassin la demi lune  france gensight is a leading company in gene therapy specialized in prevention of loss of vision and restoration of sight inception  san diego ca inception  is focused on the discovery of therapeutics for sensorineural hearing loss  the company has entered into a partnership with roche with a prenegotiated acquisition at ind viral logic systems technology seattle wa vlst corp has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases theraclone sciences seattle wa theraclone sciences inc is focused on developing novel human therapeutic antibodies for the treatment of infectious diseases acumen san francisco ca acumen is revolutionizing the diagnosis and treatment of autism and other disorders through smartphoneenabled digital behavior evaluation improving outcomes for patients and simplifying care for specialists phaserx seattle wa phaserx is developing a novel approach to intracellular delivery of macromolecules inception  san diego ca inception  is focused on oncology the company is translating biological insights into novel firstinclass small molecule drugs for cll and other oncology indications spanning both liquid and solid tumors inception  san diego ca inception  is translating biological insights into novel firstinclass small molecule drugs to treat diseases of aging ruiyi shanghai china ruiyi is a drug discovery and development company focused on firstinclass antibodies targeting g protein coupled receptors gpcrs am ventures menlo park ca am ventures is a seedstage fund focused on creating and building biotech companies portfolio companiesbiotechnology biotechnology exits  ipos medical devices medical device exits  ipos additional investments additional investment exits discovery engines case studies amira pharmaceuticals inception  inc quanticel pharmaceuticals versant venture capital vi canada lp  list of ceos founders and company directors directorpedianet  list of ceos founders board members and company directors versant venture capital vi canada lp list of persons related to the company versant venture capital vi canada lp find out list of ceos founders board members and company directors of versant venture capital vi canada lp cik number 7company address one sansome street suite  san francisco phone number former name versant venture capital vi canada lp date of change  people related to versant venture capital vi canada lp namepositionstreetcitycountrybolzon bradleyone sansome street suite  san franciscocadavis jerelone sansome street suite  san franciscocanielsen kirkone sansome street suite  san franciscocana na versant ventures vi gp lpone sansome street suite  san franciscocapraeger robinone sansome street suite  san franciscocawoiwode thomasone sansome street suite  san franciscocana versant ventures vi gpgp llcone sansome street suite  san franciscoca versant venture capital vi canada lp on the web related companiesversant affiliates fund ia lp versant affiliates fund ib lp versant affiliates fund v lp versant holdings inc versant ophthalmic affiliates i lp versant side fund i lp versant side fund ii lp versant venture capital v canada lp versant venture capital v lp versant venture capital vi lp versant venture v aiv feeder holdings lp versant venture v aiv lp versant venture capital v canada lp  list of ceos founders and company directors directorpedianet  list of ceos founders board members and company directors versant venture capital v canada lp list of persons related to the company versant venture capital v canada lp find out list of ceos founders board members and company directors of versant venture capital v canada lp cik number company address  sand hill road suite  menlo park phone number  people related to versant venture capital v canada lp namepositionstreetcitycountrybolzon bradley sand hill road suite  menlo parkcanielsen kirk sand hill road suite  menlo parkcal praeger robin sand hill road suite  menlo parkcajaffe ross sand hill road suite  menlo parkcacolella samuel sand hill road suite  menlo parkcawoiwode tom sand hill road suite  menlo parkcana versant ventures v llc sand hill road suite  menlo parkcalink william sand hill road suite  menlo parkca versant venture capital v canada lp on the web related companiesversant affiliates fund ia lp versant affiliates fund ib lp versant affiliates fund v lp versant holdings inc versant ophthalmic affiliates i lp versant side fund i lp versant side fund ii lp versant venture capital v lp versant venture capital vi canada lp versant venture capital vi lp versant venture v aiv feeder holdings lp versant venture v aiv lp versant venture capital v canada lp top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active versant venture capital v canada lp • san francisco ca • venture capital fund how do i update this listing versant venture capital v canada is based out of san francisco the firm last filed a form d notice of exempt offering of securities on  the filing was for a pooled investment fund venture capital fund the notice included securities offered of pooled investment fund interests summary dg insider form  form d  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from versant venture capital v canada lp enter your email address below and choose submit your email cancel contact info versant venture capital v canada lp one sansome street san francisco ca     business phone  recent sec filings a filed on   filed on   filed on  da filed on  schedule d and g events since 7 subscription required form   nonderivative insider transactions since 7 loading form d filings form d is a form to be used to file a notice of an exempt offering of securities with the securities and exchange commission form d contains basic information about the offering and the company form d filings filing date form type industry group securities offered total offering amount total amount sold total remaining  da pooled investment fund venture capital fund pooled investment fund interests    other issuers in filings name address versant affiliates fund v lp  sand hill road building  suite  menlo park ca  versant ophthalmic affiliates i lp  sand hill road building  suite  menlo park ca  versant venture capital v lp  sand hill road building  suite  menlo park ca  related parties included in filings name address relationship bradley bolzon subscription required director kirk nielsen subscription required director na versant ventures v llc subscription required director robin l praeger subscription required director ross jaffe subscription required director samuel colella subscription required director tom woiwode subscription required director william link subscription required director elevate your investments try it for free microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext7 about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext77 where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext77 personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext77 personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext77 personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext7 legal privacy  cookies  7 microsoft versant ventures raises  mln for sixth fund  pe hub subscribe to pe hub wire join over  of your peers get the mustread email for pevc professionals delivered to your inbox daily — for free us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions subscribe yes no registersign in a community for professionals in private capital versant ventures raises  mln for sixth fund january  7 by iris dorbian print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub versant ventures raises  mln for sixth fund versant ventures has closed its oversubscribed sixth healthcarefocused fund at a hard cap of  million fund vi will target between  and  biotech companies in the us canada and europe the firm is expected to deploy its initial investment from the fund in the first quarter of this year continue reading on pe hub writes versant ventures has closed its oversubscribed sixth healthcarefocused fund at a hard cap of  million fund vi will target between  and  biotech companies in the us canada and europe the firm is expected to deploy its initial investment from the fund in the first quarter of this year press release san francisco  vancouver british columbia  new york  basel switzerland–business wire–versant ventures today announced the close of its newest fund versant venture capital vi at its hard cap of  million versant will use its diversified global investment strategy to find form and fund innovative healthcare companies with an emphasis on novel therapeutics fund vi was highly oversubscribed and was supported by existing and new limited partners the fund will invest in  biotechnology companies in the us canada and europe versant expects to make its initial investment from the new fund in the first quarter “we are grateful to work with such highquality limited partners who have demonstrated their commitment to and belief in our strategy team and the overall potential of the healthcare sector” said versant managing director brad bolzon phd “versant has enjoyed unprecedented deal flow and outlier returns in recent years and we believe we are wellpositioned for continued success in both north america and europe” versant’s strategy has shifted to emphasize breakthrough innovation in the biotech sector and to take advantage of the firm’s broad global operating presence recent biotech acquisitions and ipos in north america and europe include quanticel novira okairos clovis crispr audentes gensight and several others the firm also has created significant capacity for company building through its three internal discovery engines and collaborations with numerous academic institutions and pharmaceutical company partners versant’s expanding discovery engines currently house more than  research scientists and now extend across several regions they include blueline bioscience in toronto highline therapeutics in new york and inception sciences in san diego vancouver and montreal one third of the future fund vi investments are expected to be derived from these engines “we’ve grown the discovery engine network from a single san diego facility in  to five fully operating research sites that cover the west coast northeast and canada and will soon extend to europe as a result of this expansion we are better enabled to invest in breakthrough academic discoveries that can be translated into lifechanging therapies for patients” said dr bolzon managing directors for fund vi are dr bolzon jerel davis phd kirk nielsen tom woiwode phd and cfo robin praeger “we are very pleased with how effectively versant has transformed a very differentiated investment strategy into a strong portfolio that is delivering toptier financial performance” said cedric bisson partner at teralys and chairman of the versant limited partner advisory committee about versant ventures versant ventures is a leading global healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies the firm invests across the healthcare sector and at all stages of company development with an emphasis on the discovery and development of novel therapeutics with  billion under management and offices in north america and europe versant has built a team with deep investment operating and scientific expertise that enables a handson approach to company building since the firm’s founding in  more than  versant companies have achieved successful acquisitions or ipos for more information please visit wwwversantventurescom print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub versant ventures raises  mln for sixth fund versant ventures has closed its oversubscribed sixth healthcarefocused fund at a hard cap of  million fund vi will target between  and  biotech companies in the us canada and europe the firm is expected to deploy its initial investment from the fund in the first quarter of this year continue reading on pe hub writes dont miss out meet new and diverse managers in private equity venture capital and real estate at the third emerging manager connect east at new york citys harvard club click here for details sign up to our newsletter receive updates from our pe hub wire and top stories of the week newsletters first name last name email address us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions you are now subscribed to the pehub wire and top stories of the week newsletters buyouts insiderargosy group llc produces several free newsletters that are sent directly to the email you provide at registration namely pe hub wire pe hub canada wire pe hub wire top story of the week buyouts daily and vcj alert to enable us to keep providing these services free of charge we reserve the right to contact you with special invitations to sample or purchase private equityrelated products by submitting this free subscription request for any of these products you are also consenting to this communication should you ever wish to unsubscribe from a particular communication you may activate the unsubscribe mechanism at the bottom of the email this will discontinue both the special invitations mentioned previously as well as your subscription to the weekly newsletter the information you provide will be safeguarded by argosy group llcbuyouts insider the company’s subsidiaries may use it to keep you informed of relevant products and services we occasionally allow reputable companies outside of the company to mail details of products which may be of interest to you as an international group we may transfer your data on a global basis for the purposes indicated above we will never share your email or contact details with any outside company however should you have any questions please do not hesitate to contact us email protected top posts kkr to buy nature’s bounty from carlyle by luisa beltran blackrock leads funding round for fintech platform icapital by iris dorbian platinum equity to buy united site services by luisa beltran the pe hub podcast episode two by staff report private equity jobs of the week priceline kpmg novaquest are hiring by eamon murphy raymond james expands team with new hire by iris dorbian the carveout curveball by pehublogger network private equity jobs of the week cambridge associates bank of america ubs are hiring by eamon murphy canadian lps anchor versant venture capital vis  mln close  pe hub subscribe to pe hub wire join over  of your peers get the mustread email for pevc professionals delivered to your inbox daily — for free us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions subscribe yes no registersign in a community for professionals in private capital canadian lps anchor versant venture capital vi’s  mln close january  7 by kirk falconer print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub canadian lps anchor versant venture capital vis  mln close us venture capital firm versant ventures has closed its sixth life sciences fund versant venture capital vi at its hardcap target of  million us million fund vi which was oversubscribed secured commitments from both new and existing limited partners including canadian investors teralys capital northleaf capital partners harbourvest canada growth fund and fonds de solidarité ftq the fund will invest in up to  healthcare companies with an emphasis on novel therapeutics in the united states canada and europe versant coled canadas largest venture round in  the us million financing of torontos bluerock therapeutics continue reading on pe hub writes us venture capital firm versant ventures has closed its sixth life sciences fund versant venture capital vi at its hardcap target of  million us million fund vi which was oversubscribed secured commitments from both new and existing limited partners including canadian investors teralys capital northleaf capital partners harbourvest canada growth fund and fonds de solidarité ftq the fund will invest in up to  healthcare companies with an emphasis on novel therapeutics in the united states canada and europe versant coled canada’s largest venture round in  the us million financing of toronto’s bluerock therapeutics press release versant ventures closes th healthcare fund firm expects continued growth of its portfolio of canadian biotechs january  7 vancouver british columbia  toronto  montreal–business wire–versant ventures today announced the close of its newest fund versant venture capital vi at its hard cap of cad million usd million versant will use its diversified global investment strategy to find form and fund innovative healthcare companies with an emphasis on novel therapeutics fund vi was highly oversubscribed and was supported by existing and new limited partners including canadian investors teralys capital northleaf venture catalyst fund harbourvest partners and fonds de solidarité ftq the fund will invest in  biotechnology companies in the us canada and europe versant expects to make its initial investment from the new fund in the first quarter “we are grateful to work with such highquality limited partners who have demonstrated their commitment to and belief in our strategy team and the overall potential of the healthcare sector” said versant managing director brad bolzon phd “versant has enjoyed unprecedented deal flow and outlier returns in recent years and we believe we are wellpositioned for continued success in both north america and europe” versant’s strategy has shifted to emphasize breakthrough innovation in the biotech sector and to take advantage of the firm’s broad global operating presence recent biotech acquisitions and ipos in north america and europe include quanticel novira okairos clovis crispr audentes gensight and several others canada in particular has become a productive source for company creation and investment for versant since  versant’s canadian footprint has grown to include three discovery engines with research sites in vancouver toronto and montreal five fully backed biotech companies two seed investments and  academic grants supported by the firm with the recent investments in bluerock therapeutics northern biologics and turnstone biologics versant’s portfolio of canadianbased biotech startups now has more than cad million in capital commitments from versant syndicate members and pharmaceutical partners managing directors for fund vi are dr bolzon jerel davis phd kirk nielsen tom woiwode phd and cfo robin praeger “we are very pleased with how effectively versant has transformed a very differentiated investment strategy into a strong portfolio that is delivering toptier financial performance” said cedric bisson partner at teralys and chairman of the versant limited partner advisory committee about versant ventures versant ventures is a leading global healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies the firm invests across the healthcare sector and at all stages of company development with an emphasis on the discovery and development of novel therapeutics with  billion under management and offices in north america and europe versant has built a team with deep investment operating and scientific expertise that enables a handson approach to company building since the firm’s founding in  more than  versant companies have achieved successful acquisitions or ipos for more information please visit wwwversantventurescom contacts versant ventures steve edelson  email protected photo courtesy of reutersmark blinch print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub canadian lps anchor versant venture capital vis  mln close us venture capital firm versant ventures has closed its sixth life sciences fund versant venture capital vi at its hardcap target of  million us million fund vi which was oversubscribed secured commitments from both new and existing limited partners including canadian investors teralys capital northleaf capital partners harbourvest canada growth fund and fonds de solidarité ftq the fund will invest in up to  healthcare companies with an emphasis on novel therapeutics in the united states canada and europe versant coled canadas largest venture round in  the us million financing of torontos bluerock therapeutics continue reading on pe hub writes dont miss out meet new and diverse managers in private equity venture capital and real estate at the third emerging manager connect east at new york citys harvard club click here for details sign up to our newsletter receive updates from our pe hub wire and top stories of the week newsletters first name last name email address us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions you are now subscribed to the pehub wire and top stories of the week newsletters buyouts insiderargosy group llc produces several free newsletters that are sent directly to the email you provide at registration namely pe hub wire pe hub canada wire pe hub wire top story of the week buyouts daily and vcj alert to enable us to keep providing these services free of charge we reserve the right to contact you with special invitations to sample or purchase private equityrelated products by submitting this free subscription request for any of these products you are also consenting to this communication should you ever wish to unsubscribe from a particular communication you may activate the unsubscribe mechanism at the bottom of the email this will discontinue both the special invitations mentioned previously as well as your subscription to the weekly newsletter the information you provide will be safeguarded by argosy group llcbuyouts insider the company’s subsidiaries may use it to keep you informed of relevant products and services we occasionally allow reputable companies outside of the company to mail details of products which may be of interest to you as an international group we may transfer your data on a global basis for the purposes indicated above we will never share your email or contact details with any outside company however should you have any questions please do not hesitate to contact us email protected top posts clairvest to sell crs to ashtead’s sunbelt rentals for 7 mln by kirk falconer novacap’s fifth techbuyout fund blows by target raises  mln by kirk falconer five questions with john ruffolo ceo of omers ventures by kirk falconer birch hill to buy ccm hockey brand from adidas for  mln by kirk falconer mitel tries again to buy shoretel in  mln deal by kirk falconer fintech platform borrowell raises  mln in vc  mln in debt by kirk falconer omers to earn x its money with 7 bln sale of civica by kirk falconer brookfield to acquire  pct of teekay offshore for 7 mln by kirk falconer microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext7 about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext77 where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext77 personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext77 personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext77 personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext7 legal privacy  cookies  7 microsoft versant ventures nabs m for biotech investment fund  law search advanced search take a free trial  sign in close law indepth law uk adv search  platform tools browse all sections banking bankruptcy class action competition employment energy expert analysis insurance intellectual property product liability securities rankings laws mvps glass ceiling report global  law  diversity snapshot practice group partner rankings practice groups of the year pro bono firms of the year rising stars trial aces site menu join the law team search legal jobs learn more about law read testimonials contact law sign up for our newsletters site map help make sure you dont miss any law breaking news download our plugin for chrome to get customizable realtime news alerts versant ventures nabs m for biotech investment fund by benjamin horney law new york january  7  pm est  versant ventures a private investment firm focused on the health care industry on tuesday said that it has closed its latest fund after raising  million from investors with plans to invest in up to  biotechnology companies across north america and europethe fund versant venture capital vi lp raked in capital from investors old and new according to a statement with limited partners including teralys capital northleaf venture catalyst fund harbourvest partners and fonds de solidarite ftq among others versant venture capital vi will to view the full article register now try law free for seven days already a subscriber click here to login add to briefcase printable version rightsreprints editorial contacts related sections health life sciences private equity companies bayer ag harbourvest partners llc versant ventures inc government agencies securities and exchange commission check out laws new podcast pro say which offers a weekly recap of both the biggest stories and hidden gems from the world of law listen to our latest most popular  ny high court judges death ruled a suicide  linklaters atty denies link to husbands alleged fraud  how to manage health care costs and keep lawyers happy  apple vs qualcomm battle heats up what you need to know  dentons scores atty patent team from mofo × already have access click here to login get instant access to the onestop news source for business lawyers register now get instant access to the onestop news source for business lawyers email professional email required first name last name please note a verification email will be sent to your address before you can access your trial password at least  characters required confirm password select at least one primary interest health life sciences private equity show all interests aerospace  defense appellate asset management automotive banking bankruptcy california capital markets class action commercial contracts competition consumer protection corporate cybersecurity  privacy delaware employment energy environmental financial services uk florida food  beverage government contracts hospitality illinois immigration insurance insurance uk intellectual property international arbitration international trade law in depth legal ethics media  entertainment medical malpractice mergers  acquisitions native american new jersey new york pennsylvania product liability project finance public policy real estate retail  e commerce securities sports tax technology telecommunications texas transportation trials white collar register already have access email password forgot your password remember login sign in × sign up for our free health newsletter you must correct or enter the following before you can sign up please provide a professional email select more newsletters to receive for free aerospace  defense appellate asset management automotive banking bankruptcy california capital markets class action commercial contracts competition consumer protection corporate cybersecurity  privacy delaware employment energy environmental florida food  beverage government contracts health hospitality illinois immigration insurance intellectual property international arbitration international trade law indepth legal ethics legal industry life sciences media  entertainment medical malpractice mergers  acquisitions native american new jersey new york pennsylvania private equity product liability project finance public policy real estate retail  ecommerce securities sports tax technology telecommunications texas transportation trials white collar no thanks sign up now thank you versant ventures closes fund vi in record time  private capital journal skip to content saturday july  7 versant ventures closes fund vi in record time by ted liu  january  7january  7 vc funds british columbia biotech and life sciences ontario quebec united states versant ventures has closed its newest fund versant venture capital vi at its hard cap of us  million or cdn  million and in a record time exactly two months versant venture capital vi family of funds consists of a delaware main fund versant venture capital vi lp and an ontario parallel fund versant venture capital vi canada lp there are no breakdown on the sizes of the two funds canadian limited partners lps include three vcap fund of funds teralys capital northleaf venture catalyst fund harbourvest partners and retail fund fonds de solidarité ftq the quick closing is likely aided by its recent blockbuster deals that versant engineered and brought to canada including us m in bluerock therapeutics us m in turnstone biologics and northern biologics’ pharma development deal fund vi will invest in  biotechnology companies in the us canada and europe versant ventures expects to make its initial investment from the new fund in the first quarter managing directors for fund vi are dr bolzon jerel davis phd kirk nielsen tom woiwode phd and cfo robin praeger photo credit versant share this story share on facebook share  share on linkedin share  share on google plus share  share on twittertweet  share on pinterest share  share on digg share send email mail ted liu ted liu msc mba is the editor of private capital journal and former editor of canadian private equity a seasoned researcher ted has been passionately tracking canadian private capital industry since  ted most recently served as research director for canadian venture capital and private equity association cvca from  to  similar articles novarc technologies secures m seed financing march  7april  7 zymeworks files nd amendment for up to us m ipo april  7april  7 connect with us latest posts mundo pulls m ipo july  7july  7 ottp’s busy bees closes m acquisition of brightpath july  7 tso logic secures new financing july  7july  7 birch hill equity partners to acquire ccm for us m july 7 7july 7 7 osram acquires stake in bdc capital backed leddartech july 7 7 cdpq acquires cascades’ 7 interest in boralex for 7m july 7 7july 7 7 bentall kennedy high yield canadian property fund i first closes at m july 7 7july 7 7 precithera closes m series a coled by sanderling ventures arix bioscience july 7 7july 7 7 champlain financial combines riverside lobster with cheticamp fisheries july  7 top